Invetx Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
4
Invetx General Information
Description
Developer of a biotechnology innovation platform designed to build protein-based therapeutics. The company's platform uses deep expertise and is focused on guiding the development of a portfolio of therapies and technologies to deliver the future of animal care, enabling users to gain access to biopharma technology for pets and farm animal populations.
Contact Information
Website
www.invetx.com(Operating Subsidiary)
Corporate Office
- One Boston Place
- Suite 3930, 201 Washington Street
- Boston, MA 02108
- United States
Corporate Office
- One Boston Place
- Suite 3930, 201 Washington Street
- Boston, MA 02108
- United States
Invetx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Invetx Comparisons
Industry
Financing
Details
Invetx Competitors (3)
One of Invetx’s 3 competitors is Scout Bio, a Private Equity-Backed company based in Philadelphia, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Scout Bio | Private Equity-Backed | Philadelphia, PA | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany | ||||
| Ironwood Pharmaceuticals | Formerly VC-backed | Boston, MA |
Invetx Patents
Invetx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240392009-A1 | Pharmaceutical compositions for antibodies and making and using the same | Pending | 22-May-2023 | ||
| US-20240209096-A1 | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use | Pending | 27-Dec-2022 | ||
| US-20240209062-A1 | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use | Pending | 27-Dec-2022 | ||
| CA-3238769-A1 | Anti-ngf antibodies and uses thereof | Pending | 23-Nov-2021 | ||
| US-20240199727-A1 | Anti-ngf antibodies and uses thereof | Pending | 23-Nov-2021 | C07K16/22 |
Invetx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Invetx Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Invetx FAQs
-
When was Invetx founded?
Invetx was founded in 2018.
-
Where is Invetx headquartered?
Invetx is headquartered in Boston, MA.
-
What is the size of Invetx?
Invetx has 11 total employees.
-
What industry is Invetx in?
Invetx’s primary industry is Other Healthcare Technology Systems.
-
Is Invetx a private or public company?
Invetx is a Private company.
-
What is the current valuation of Invetx?
The current valuation of Invetx is .
-
What is Invetx’s current revenue?
The current revenue for Invetx is .
-
How much funding has Invetx raised over time?
Invetx has raised $86M.
-
Who are Invetx’s investors?
AbCellera, Abrdn, Anterra Capital, Casdin Capital, and Eight Roads are 5 of 10 investors who have invested in Invetx.
-
Who are Invetx’s competitors?
Scout Bio, Boehringer Ingelheim, and Ironwood Pharmaceuticals are competitors of Invetx.
-
When was Invetx acquired?
Invetx was acquired on 18-Jul-2024.
-
Who acquired Invetx?
Invetx was acquired by Dechra Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
